RNAi for common diseases? Alnylam plans to forge a path forward, starting with new obesity gene target
Just over a month after it scored an approval for a next-gen RNAi therapy for hATTR amyloidosis, Alnylam has unveiled a bit more on where it plans to go next.
The Cambridge, MA-based biopharma announced Wednesday morning that it would be putting its RNAi technology toward some much, much broader indications — cardiometabolic diseases, which implicates a broad range of conditions, such as heart disease, diabetes and stroke, that collectively are the leading cause of death in the world.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.